Treatment of Class V Lupus Nephritis
For class V (membranous) lupus nephritis, initiate treatment with glucocorticoids combined with mycophenolate (MMF/MPA) as first-line therapy, with calcineurin inhibitors (CNIs) such as tacrolimus or voclosporin as strong alternatives, particularly for patients with nephrotic-range proteinuria or those who cannot tolerate MMF. 1
Initial Treatment Approach
The treatment strategy for class V LN depends on the severity of proteinuria and presence of nephrotic syndrome:
For Nephrotic-Range Proteinuria (>3.5 g/day)
The evidence supporting CNIs in class V LN is particularly compelling. Tacrolimus demonstrates faster resolution of proteinuria compared to conventional cytotoxic therapy, with 76.2% reduction in proteinuria at 12 weeks versus 47.1% with cyclophosphamide/azathioprine 3. Additionally, CNI-treated patients show lower rates of lupus flares within the first year 3.
For Sub-Nephrotic Proteinuria
- Monitor closely with supportive care
- Consider immunosuppression if proteinuria persists or worsens
- Implement renin-angiotensin system blockade for proteinuria management 1
Maintenance Therapy
Continue maintenance immunosuppression for at least 3 years to reduce risk of renal flares 4. Options include:
- MMF/MPA (preferred if used for induction) 1
- Azathioprine 2 mg/kg/day 1
- Tacrolimus (trough 4-6 ng/ml) - particularly effective for patients with persistent proteinuria 1
- Glucocorticoids: Taper to ≤5 mg/day prednisone equivalent 1, 2
The KDIGO 2024 guidelines emphasize that tacrolimus was superior to azathioprine in preventing kidney relapse during maintenance, with zero relapses in the tacrolimus group versus 2 in the azathioprine group over 6 months 1.
Add-On Therapy Considerations
For patients with inadequate response to initial therapy, adding a CNI to ongoing MMF therapy is effective for reducing proteinuria, especially when baseline kidney biopsy shows podocyte injury features 1. This approach is supported by multiple case series demonstrating efficacy in Asian populations, though it's reasonable to apply across all ethnic groups 1.
Biological Agents
- Belimumab: Can be added to standard therapy (MMF or azathioprine + low-dose glucocorticoids), with sustained efficacy through 104 weeks and lower rates of adverse kidney outcomes 1
- Consider in patients at significant risk of disease progression 4
Treatment Targets and Monitoring
Aim for the following proteinuria reduction milestones:
- 3 months: ≥25% reduction
- 6 months: ≥50% reduction
- 12 months: Complete renal response (<500-700 mg/day) 5
Critical Caveats
Avoid chronic CNI nephrotoxicity by:
- Ensuring histologic evidence of podocyte injury before adding CNI 1
- Being particularly cautious in patients with pre-existing CKD 1
- Monitoring trough levels carefully
- Avoiding overimmunosuppression with multiple agents 1
Pregnancy considerations: Tacrolimus and cyclosporine can be used safely during pregnancy, while leflunomide is contraindicated and requires discontinuation at least 2 years before conception 1.
Alternative Agents
If MMF and azathioprine cannot be used:
- CNIs (tacrolimus, cyclosporine, voclosporin)
- Mizoribine
- Leflunomide (only as last resort, contraindicated in pregnancy) 1
The evidence base for class V LN treatment is moderate quality 5, but the consistent findings across multiple studies support CNIs as highly effective alternatives to traditional cytotoxic therapy, with potentially faster proteinuria reduction and better safety profiles.